Yilmaz, M <br/><br/>
Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Jul 2012 
 - 2059-62 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1433-2965 
<br/><br/><label>Standard No.: </label>10.1007/s00198-011-1836-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alendronate--adverse effects<br/>Bone Density Conservation Agents--adverse effects<br/>Humans<br/>Male<br/>Nephrotic Syndrome--chemically induced<br/>Osteoporosis--drug therapy